News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
426,159 Results
Type
Article (34706)
Company Profile (66)
Press Release (391377)
Multimedia
Podcasts (101)
Webinars (9)
Section
Business (115627)
Career Advice (1392)
Deals (24460)
Drug Delivery (134)
Drug Development (60692)
Employer Resources (111)
FDA (10491)
Job Trends (9305)
News (216049)
Policy (25903)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (4)
Academia (1897)
Accelerated approval (50)
ADA (31)
Adcomms (32)
Allergies (150)
Alliances (42538)
ALS (155)
Alzheimer's disease (1481)
Antibody-drug conjugate (ADC) (404)
Approvals (10729)
Artificial intelligence (481)
ASCO (232)
Autoimmune disease (223)
Automation (34)
Bankruptcy (241)
Best Places to Work (7761)
BIO (39)
BIOSECURE Act (16)
Biosimilars (190)
Biotechnology (45)
Bladder cancer (152)
Brain cancer (76)
Breast cancer (553)
Cancer (4640)
Cardiovascular disease (369)
Career advice (1193)
Career pathing (30)
CAR-T (239)
CDC (71)
Cell therapy (672)
Cervical cancer (40)
Clinical research (52685)
Collaboration (1820)
Company closure (5)
Compensation (1277)
Complete response letters (87)
COVID-19 (2648)
CRISPR (82)
C-suite (643)
Cystic fibrosis (94)
Data (6175)
Decentralized trials (2)
Denatured (13)
Depression (131)
Dermatology (72)
Diabetes (508)
Diagnostics (3915)
Digital health (33)
Diversity (9)
Diversity, equity & inclusion (35)
Drug discovery (261)
Drug pricing (199)
Drug shortages (32)
Duchenne muscular dystrophy (260)
Earnings (44468)
Editorial (70)
Employer branding (18)
Employer resources (104)
Events (50653)
Executive appointments (553)
FDA (13367)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (16)
Frontotemporal dementia (27)
Funding (1207)
Gene editing (176)
Generative AI (49)
Gene therapy (598)
GLP-1 (1081)
Government (4503)
Grass and pollen (6)
Guidances (328)
Healthcare (11629)
Hematology (142)
HIV (73)
Huntington's disease (52)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (90)
Immunology and inflammation (226)
Immuno-oncology (84)
Indications (162)
Infectious disease (3002)
Inflammatory bowel disease (142)
Inflation Reduction Act (11)
Influenza (138)
Intellectual property (202)
Interviews (247)
IPO (10628)
IRA (48)
Job creations (1831)
Job search strategy (1000)
JPM (50)
Kidney cancer (14)
Labor market (73)
Layoffs (389)
Leadership (29)
Legal (7134)
Liver cancer (77)
Longevity (34)
Lung cancer (631)
Lymphoma (361)
Machine learning (41)
Management (33)
Manufacturing (817)
Marketing (1)
MASH (184)
Medical device (6170)
Medtech (6235)
Mergers & acquisitions (14858)
Metabolic disorders (1424)
mRNA (208)
Multiple sclerosis (144)
NASH (21)
Neurodegenerative disease (357)
Neuropsychiatric disorders (92)
Neuroscience (2695)
Neurotech (1)
NextGen: Class of 2026 (3752)
Non-profit (2834)
Now hiring (15)
Obesity (722)
Opinion (282)
Ovarian cancer (163)
Pain (158)
Pancreatic cancer (274)
Parkinson's disease (293)
Partnered (25)
Patents (396)
Patient recruitment (464)
Peanut (53)
People (27808)
Pharmaceutical (19)
Pharmacy benefit managers (22)
Phase 1 (15909)
Phase 2 (22925)
Phase 3 (18585)
Pipeline (7305)
Policy (332)
Postmarket research (1868)
Preclinical (6616)
Press Release (28)
Prostate cancer (251)
Psychedelics (53)
Radiopharmaceuticals (291)
Rare diseases (930)
Real estate (2668)
Recruiting (50)
Regulatory (18995)
Reports (27)
Research institute (1666)
Resumes & cover letters (212)
Rett syndrome (40)
RNA editing (15)
RSV (91)
Schizophrenia (152)
Series A (174)
Series B (138)
Service/supplier (3)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (162)
Sponsored (32)
Startups (2052)
State (1)
Stomach cancer (14)
Supply chain (105)
Tariffs (86)
The Weekly (87)
Vaccines (1162)
Venture capital (98)
Weight loss (491)
Women's health (82)
Worklife (13)
Date
Today (64)
Last 7 days (296)
Last 30 days (1738)
Last 365 days (20003)
2026 (10313)
2025 (20090)
2024 (22579)
2023 (25476)
2022 (33712)
2021 (36280)
2020 (34394)
2019 (28266)
2018 (21535)
2017 (20521)
2016 (18927)
2015 (21725)
2014 (16137)
2013 (12995)
2012 (13786)
2011 (14549)
2010 (13211)
Location
Africa (603)
Alabama (58)
Alaska (3)
Arizona (142)
Arkansas (6)
Asia (27786)
Australia (4961)
California (8563)
Canada (2484)
China (1073)
Colorado (341)
Connecticut (414)
Delaware (306)
Europe (67062)
Florida (1311)
Georgia (268)
Hawaii (4)
Idaho (31)
Illinois (664)
India (72)
Indiana (418)
Iowa (19)
Japan (479)
Kansas (86)
Kentucky (32)
Louisiana (35)
Maine (36)
Maryland (1178)
Massachusetts (6086)
Michigan (196)
Minnesota (304)
Mississippi (1)
Missouri (93)
Montana (21)
Nebraska (12)
Nevada (91)
New Hampshire (35)
New Jersey (2518)
New Mexico (17)
New York (2435)
North Carolina (1016)
North Dakota (6)
Northern California (4425)
Ohio (235)
Oklahoma (11)
Oregon (14)
Pennsylvania (1711)
Puerto Rico (18)
Rhode Island (19)
South America (825)
South Carolina (42)
South Dakota (1)
Southern California (3355)
Tennessee (113)
Texas (1139)
United States (30104)
Utah (193)
Vermont (2)
Virginia (228)
Washington D.C. (45)
Washington State (660)
West Virginia (2)
Wisconsin (83)
Wyoming (2)
426,159 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement will see Novartis pay $40 million upfront.
June 11, 2026
·
2 min read
·
Tristan Manalac
Deals
Novartis, Antares stars align in cancer deal that could top $1.9B
Novartis and Antares Therapeutics are shooting for the stars, launching a joint mission to develop small molecule oncology therapies.
June 24, 2026
·
2 min read
·
Gabrielle Masson
Funding
NewLimit snags $435M after seeing age reversal in human liver cells
NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells.
June 3, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
March 15, 2026
·
11 min read
Neurodegenerative disease
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
June 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
DeepoMe Introduces the First Biomedical World Model for Chronic Disease Management and Aging Intervention
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging
May 26, 2026
·
1 min read
Huntington’s disease
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval
Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more than 50%. Analysts say the decision to initiate a last-stage trial reflects a lack of confidence in an accelerated FDA nod.
April 29, 2026
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
May 26, 2026
·
9 min read
·
Heather McKenzie
Earnings
Novartis’ sales dip as generics pressure intensifies, radioequivalents loom
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
April 28, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Niowave, fresh from Novartis deal, starts building $75M radioisotope plant
Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.
May 26, 2026
·
2 min read
·
Nick Paul Taylor
1 of 42,616
Next
